| 摘要 |
Disclosed is the use of a bG-CSF-T133pAF-20K PEG, a citrate or succinate buffer, arginine, and optionally a counter ion for arginine in the manufacture of a medicament for treatment of a disorder modulated by bG-CSF, wherein the medicament is a stable aqueous formulation containing less than 0.001% of a surfactant. Also disclosed is a stable aqueous formulation comprising bG-CSF-T133pAF-20K PEG, a citrate or succinate buffer, arginine, and optionally a counter ion for arginine, wherein said formulation contains less than 0.001% of a surfactant. |
